University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

Simple item page
dc.contributor.authorWheeler, Cosette M.
dc.contributor.authorSkinner, S. Rachel
dc.contributor.authorRowena Del Rosario-Raymundo, M.
dc.contributor.authorGarland, Suzanne M.
dc.contributor.authorChatterjee, Archana
dc.contributor.authorLazcano-Ponce, Eduardo
dc.contributor.authorSalmeron, Jorge
dc.contributor.authorMcNeil, Shelly
dc.contributor.authorStapleton, Jack T.
dc.contributor.authorBouchard, Celine
dc.contributor.authorMartens, Mark G.
dc.contributor.authorMoney, Deborah M.
dc.contributor.authorQuek, Swee Chong
dc.contributor.authorRomanowski, Barbara
dc.contributor.authorVallejos, Carlos S.
dc.contributor.authorter Harmsel, Bram
dc.contributor.authorPrilepskaya, Vera
dc.contributor.authorFong, Kah Leng
dc.contributor.authorKitchener, Henry
dc.contributor.authorMinkina, Galina
dc.contributor.authorLim, Yong Kuei Timothy
dc.contributor.authorStoney, Tanya
dc.contributor.authorChakhtoura, Nahida
dc.contributor.authorCruickshank, Margaret E.
dc.contributor.authorSavicheva, Alevtina
dc.contributor.authorda Silva, Daniel Pereira
dc.contributor.authorFerguson, Murdo
dc.contributor.authorMolijn, Anco C.
dc.contributor.authorQuint, Wim G. V.
dc.contributor.authorHardt, Karin
dc.contributor.authorDescamps, Dominique
dc.contributor.authorSuryakiran, Pemmaraju V.
dc.contributor.authorKarkada, Naveen
dc.contributor.authorGeeraerts, Brecht
dc.contributor.authorDubin, Gary
dc.contributor.authorStruyf, Frank
dc.contributor.authorVIVIANE Study Group
dc.contributor.institutionUniversity of Aberdeen.Medical Educationen
dc.date.accessioned2016-12-29T00:30:48Z
dc.date.available2016-12-29T00:30:48Z
dc.date.embargoedUntil2016-12-28
dc.date.issued2016-10
dc.descriptionAcknowledgments The VIVIANE study was funded and coordinated by GlaxoSmithKline Biologicals SA, which also covered all costs associated with development and publication of this report. We thank all study participants and their families. We gratefully acknowledge the work of the central and local study coordinators, and staff members of the sites who participated in this study. Writing support services were provided by Mary Greenacre (An Sgriobhadair, Isle of Barra, UK), on behalf of GSK Vaccines; editing and publication coordination services were provided by Jérôme Leemans (Keyrus Biopharma, Lasne, Belgium), Stéphanie Delval (XPE Pharma and Science, Wavre, Belgium), and Matthieu Depuydt (Business Decision Life Sciences, Brussels, Belgium), on behalf of GSK Vaccinesen
dc.description.statusPeer revieweden
dc.format.extent15
dc.format.extent213761
dc.identifier66682755
dc.identifier14a3eefe-f196-47b1-8327-eb3d67b8da59
dc.identifier000383469000038
dc.identifier84977668330
dc.identifier000383469000038
dc.identifier.citationWheeler, C M, Skinner, S R, Rowena Del Rosario-Raymundo, M, Garland, S M, Chatterjee, A, Lazcano-Ponce, E, Salmeron, J, McNeil, S, Stapleton, J T, Bouchard, C, Martens, M G, Money, D M, Quek, S C, Romanowski, B, Vallejos, C S, ter Harmsel, B, Prilepskaya, V, Fong, K L, Kitchener, H, Minkina, G, Lim, Y K T, Stoney, T, Chakhtoura, N, Cruickshank, M E, Savicheva, A, da Silva, D P, Ferguson, M, Molijn, A C, Quint, W G V, Hardt, K, Descamps, D, Suryakiran, P V, Karkada, N, Geeraerts, B, Dubin, G, Struyf, F & VIVIANE Study Group 2016, 'Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study', Lancet Infectious Diseases, vol. 16, no. 10, pp. 1154-1168. https://doi.org/10.1016/S1473-3099(16)30120-7en
dc.identifier.doi10.1016/S1473-3099(16)30120-7
dc.identifier.iss10en
dc.identifier.issn1473-3099
dc.identifier.otherORCID: /0000-0002-8893-8620/work/102132251
dc.identifier.urihttp://hdl.handle.net/2164/7913
dc.identifier.vol16en
dc.language.isoeng
dc.relation.ispartofLancet Infectious Diseasesen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectOF-STUDY ANALYSISen
dc.subjectINTRAEPITHELIAL NEOPLASIAen
dc.subjectQUADRIVALENT VACCINEen
dc.subjectSUSTAINED EFFICACYen
dc.subjectCONTROLLED-TRIALen
dc.subjectHPV VACCINATIONen
dc.subjectCERVICAL-CANCERen
dc.subjectPATRICIA TRIALen
dc.subjectBROAD-SPECTRUMen
dc.subjectYOUNG-WOMENen
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleEfficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years : 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
New_RV_Wheeler_et_al_The_Lancet_ID.docx
Size:
208.75 KB
Format:
Unknown data format
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
8.29 KB
Format:
Plain Text
Description:
Download

Collections

All research
Medical & Dental Education research
University Office research